Secondary male hypogonadism
ICD-10 E29.1 · ICD-11 5A81.1.1

What Is the First-Line Treatment for Secondary Male Hypogonadism?

This page summarises the structured, evidence-based first-line approach to secondary male hypogonadism. The complete regimen — including agent selection, preparation-specific guidance, and the full decision pathway — is available through the link below.

Treatment Approach

Testosterone replacement therapy is the primary intervention. When initiating treatment, short-acting preparations are preferred over long-acting depot formulations, so that therapy can be adjusted or discontinued promptly should adverse effects arise. Multiple delivery routes exist — the full selection criteria and individualized regimen remain in the complete protocol.

Complete agent selection, preparation details, and the clinical decision pathway are in the full protocol.

Treatment Goals

The aim is to restore serum testosterone to the mid-normal range for the patient's age group, with regression of hypogonadal symptoms. Response is assessed at three, six, and twelve months after treatment onset, and annually thereafter.

Instant Access to Structured Evidence-Based Regimens

References

View source ↗